These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30632889)

  • 1. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy.
    Wiedower JA; Forbes SP; Tsai LJ; Liao J; Raez LE
    J Manag Care Spec Pharm; 2024 Jul; 30(7):660-671. PubMed ID: 38950156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of barriers to implementation of precision oncology in patients with rare cancers.
    Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
    Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
    Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
    Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
    Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
    JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
    Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
    Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice.
    Čerina D; Matković V; Katić K; Lovasić IB; Šeparović R; Canjko I; Jakšić B; Fröbe A; Pleština S; Bajić Ž; Vrdoljak E
    Pathol Oncol Res; 2021; 27():1609963. PubMed ID: 34646088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive genomic profiling for oncological advancements by precision medicine.
    Pankiw M; Brezden-Masley C; Charames GS
    Med Oncol; 2023 Nov; 41(1):1. PubMed ID: 37993657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
    Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
    Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer.
    Tjota MY; Segal JP; Wang P
    J Appl Lab Med; 2024 Jan; 9(1):76-91. PubMed ID: 38167763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
    Suh JH; Schrock AB; Johnson A; Lipson D; Gay LM; Ramkissoon S; Vergilio JA; Elvin JA; Shakir A; Ruehlman P; Reckamp KL; Ou SI; Ross JS; Stephens PJ; Miller VA; Ali SM
    Oncologist; 2018 Jul; 23(7):776-781. PubMed ID: 29540602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling in oncology clinical practice.
    Rodríguez N; Viñal D; Rodríguez-Cobos J; De Castro J; Domínguez G
    Clin Transl Oncol; 2020 Sep; 22(9):1430-1439. PubMed ID: 31981077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
    Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
    Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.